首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1734250

轉移性大腸直腸癌市場（按藥物類別和地區）分析與預測（2025-2035）

Global Metastatic Colorectal Cancer Market: Focus on Drug Class, and Region - Analysis and Forecast, 2025-2035

出版日期: 2025年05月28日 | 出版商:

BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄圖表

全球轉移性大腸直腸癌 (mCRC) 市場是腫瘤製藥行業的一個重要領域，其發展受到結直腸癌發病率上升、治療技術的進步以及對改善患者預後的日益關注的推動。

轉移性大腸直腸癌是起源於結腸或直腸並擴散至肝臟或肺等遠端器官的癌症。 mCRC 是一種複雜且侵襲性的癌症，通常預後不良且治療選擇有限。因此，mCRC 市場對有效治療方法不僅可以控制疾病，還可以延長生存期並改善患者的生活品質。

標靶治療的引入是轉移性大腸直腸癌市場最重大的進步之一。Bevacizumab（Avastin）和Cetuximab（Erbitux）等藥物已被開發用於特異性針對與癌細胞生長和轉移有關的分子通路，與傳統化療相比，它們提供了更有效的治療選擇，且副作用更少。這些治療方法通常與化療相結合，以提高療效，特別是在疾病廣泛擴散的情況下。此外，針對特定突變的新型單株抗體和小分子抑制劑，如表皮生長因子受體（EGFR）抑制劑和血管內皮生長因子（VEGF）抑制劑，具有進一步先進的治療選擇。

mCRC 治療中最令人興奮的進展之一是免疫療法的出現。免疫療法是治療方法。免疫查核點抑制劑，如Pembrolizumab(Keytruda) 和Nivolumab(Opdivo )，已對某些 mCRC 患者表現出顯著療效，尤其是那些微衛星不穩定性高 (MSI-H) 或錯配修復缺陷 (dMMR) 腫瘤患者。這些患者是 mCRC 患者的一個子集，由於免疫查核點抑制劑重新運作人體對癌症的免疫反應，他們的整體存活期和無惡化生存期存活期可以顯著改善。

除了這些治療方法之外，轉移性大腸直腸癌市場越來越關注聯合治療結合不同類別的多種藥物以最大限度地提高治療效果。例如，化療與標靶治療和免疫治療相結合在臨床試驗中已顯示出良好的效果，可延長晚期疾病患者的生存期並提高其生活品質。

個人化醫療的興起也是轉移性大腸直腸癌市場的關鍵趨勢。基因序列測定和生物標記識別的進步使腫瘤學家能夠根據患者腫瘤的特徵制定治療方案，確保更精確、更有效的治療。個人化醫療也促進了分子診斷的使用，幫助選擇最有可能受益於特定治療的患者，最佳化治療結果並最大限度地減少不必要的副作用。

全球轉移性大腸直腸癌市場具有高度創新的特點，多家製藥和生物技術公司積極致力於開發新的治療方法。這些公司擁有廣泛的開發平臺，其中許多公司正在從事臨床試驗，旨在發現新的分子標靶和創新藥物配方，以改善 mCRC 的治療。

此外，專注於免疫療法和新型藥物輸送系統的新興生物技術公司正擴大進入轉移性大腸直腸癌市場。這些公司通常處於新科學發展的前沿，致力於透過開發針對該疾病特定分子亞型的標靶治療來解決轉移性結直腸癌治療中未滿足的需求，為未來更有效的治療帶來希望。

影響

預計轉移性大腸直腸癌需求的不斷成長將在 2025-2035 年預測期內支持全球轉移性大腸直腸癌市場的成長。
由於藥物開發的持續進步，包括標靶治療和個人化醫療，預計市場將以顯著的速度成長，這為引入治療轉移性結直腸癌的新療法提供了巨大的機會。

根據地區來看，轉移性大腸直腸癌市場在所有地區都經歷顯著的成長。北美繼續成為轉移性大腸直腸癌治療的最大市場，這得益於其高盛行率、發達的醫療保健基礎設施以及主要企業的存在。美國是一個關鍵市場，擁有先進的醫療保健和尖端癌症治療方法，而歐洲也是一個關鍵市場，因為該地區擁有高標準的醫療保健和不斷增加的癌症研究投資。由於確診病例數增加、認知度提高以及醫療保健可近性的改善，預計亞太地區將在未來幾年內出現最高成長，尤其是在中國和印度等國家。

本報告研究了全球轉移性大腸直腸癌市場，概述了市場狀況以及藥物類別、地區和參與市場的公司概況的趨勢。

競爭格局
- 關鍵發展和策略
公司簡介
- Amgen Inc.
- Pfizer Inc.
- Eli Lilly and Company
- Sanofi
- Merck KGaA
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Taiho Oncology
- Bristol-Myers Squibb Company
- Johnson & Johnson Services, Inc.
- Shanghai Henlius Biotech
- Inspirna
- Treos Bio

第5章調查方法

簡介目錄圖表

Product Code: BHL2877SA

Global Metastatic Colorectal Cancer Market, Analysis and Forecast: 2025-2035

The global metastatic colorectal cancer (mCRC) market represents a critical segment within the oncology pharmaceutical industry, driven by the increasing incidence of colorectal cancer, advancements in therapeutic technologies, and a growing emphasis on improving patient outcomes. Metastatic colorectal cancer refers to a stage of colorectal cancer where the disease has spread from the original site in the colon or rectum to other parts of the body, often the liver, lungs, or other distant organs. It is a complex and aggressive form of cancer, typically associated with poor prognosis and limited treatment options. As a result, the mCRC market is characterized by high demand for effective therapies that can not only manage the disease but also extend survival and improve the quality of life for patients.

The introduction of targeted therapies has been one of the most significant advancements in the metastatic colorectal cancer market. Drugs such as bevacizumab (Avastin) and cetuximab (Erbitux) have been developed to specifically target the molecular pathways involved in cancer cell growth and metastasis, offering more effective treatment options with fewer side effects compared to traditional chemotherapy. These therapies are often used in combination with chemotherapy to improve efficacy, particularly in cases where the disease has spread extensively. Additionally, newer monoclonal antibodies and small molecule inhibitors targeting specific mutations, such as epidermal growth factor receptor (EGFR) inhibitors and vascular endothelial growth factor (VEGF) inhibitors, have further advanced treatment options.

One of the most transformative developments in the treatment of mCRC has been the advent of immunotherapy. Immunotherapy represents a class of treatments that harness the body's immune system to recognize and attack cancer cells. Immune checkpoint inhibitors, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), have demonstrated impressive efficacy in certain mCRC patients, particularly those with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. These patients, who represent a subset of the mCRC population, can experience significant improvements in overall survival and progression-free survival due to the ability of immune checkpoint inhibitors to reactivate the body's immune response against the cancer.

In addition to these treatment, the metastatic colorectal cancer market is witnessing a growing focus on combination therapies, where multiple drugs from different classes are used in tandem to maximize treatment efficacy. For instance, combining chemotherapy with targeted therapies or immunotherapies has shown promising results in clinical trials, leading to longer survival times and improved quality of life for patients with advanced disease.

The emergence of personalized medicine is another pivotal trend within the metastatic colorectal cancer market. With advancements in genomic sequencing and biomarker identification, oncologists can now tailor treatments to the individual characteristics of a patient's tumor, ensuring more precise and effective therapies. Personalized medicine also facilitates the use of molecular diagnostics, which help in selecting patients who are most likely to benefit from specific therapies, thus optimizing treatment outcomes and minimizing unnecessary side effects.

The global metastatic colorectal cancer market is characterized by a high level of innovation, with several pharmaceutical companies and biotechnology firms actively involved in the development of novel therapies. The companies have large R&D pipelines, and many of them are engaged in clinical trials aimed at discovering new molecular targets and innovative drug formulations to improve mCRC treatment.

Additionally, emerging biotech companies focusing on immunotherapy and novel drug delivery systems are increasingly entering the metastatic colorectal cancer market. These companies are often at the forefront of new scientific developments, seeking to address the unmet needs in the treatment of metastatic colorectal cancer by developing targeted therapies for specific molecular subtypes of the disease, offering hope for more effective treatments in the future.

Impact

Increasing demand for metastatic colorectal cancer is anticipated to support the growth of the global metastatic colorectal cancer market during the forecast period 2025-2035.
The market is expected to grow at a significant growth rate due to opportunities such as the Continued advancements in drug development, including targeted therapies and personalized medicine, offer significant opportunities for the introduction of novel therapies for metastatic colorectal cancer treatment.

Market Segmentation:

Segmentation 1: by Drug Class

Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors
Anti-VEGF (Vascular Endothelial Growth Factor) Therapies
Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies
Immune Checkpoint Inhibitors
Others

Segmentation 2: by Region

North America
Europe
Asia-Pacific

Geographically, the metastatic colorectal cancer market is witnessing substantial growth across all regions. North America remains the largest market for mCRC therapies, driven by the high prevalence of the disease, significant healthcare infrastructure, and the presence of leading pharmaceutical companies. The U.S. is a key market, with access to advanced healthcare and cutting-edge cancer treatments, while Europe also represents a significant market due to the high standards of healthcare in the region and increasing investments in oncology research. Asia-Pacific is expected to experience the highest growth in the coming years, driven by the increasing number of diagnosed cases, rising awareness, and improved healthcare access, particularly in countries like China and India.

Executive Summary

Scope and Definition

Market/Product Definition

Key Questions Answered

Analysis and Forecast Note

1. Global Metastatic Colorectal Cancer Market: Industry Outlook

1.1 Market Overview
1.2 Epidemiological Analysis of Metastatic Colorectal Cancer
- 1.2.1 By Region
1.3 Regulatory Landscape of Global Metastatic Colorectal Cancer Market
- 1.3.1 Legal Requirement and Framework in the U.S.
- 1.3.2 Legal Requirement and Framework in the E.U.
1.4 Key Trends
1.5 Clinical Trial Analysis
1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.3 Market Restraint
- 1.6.4 Market Opportunities

2. Global Metastatic Colorectal Cancer Market, by Drug Class, $Million, 2023-2035

2.1 Overview
2.2 Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors
2.3 Anti-VEGF (Vascular Endothelial Growth Factor) Therapies
2.4 Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies
2.5 Immune Checkpoint Inhibitors
2.6 Others

3. Global Metastatic Colorectal Cancer Market, by Region, $Million, 2023-2035

3.1 North America
- 3.1.1 Key Market Participants in North America
- 3.1.2 Business Drivers
- 3.1.3 Business Challenges
- 3.1.4 Market Sizing and Forecast
  - 3.1.4.1 North America Metastatic Colorectal Cancer Market, by Country
    - 3.1.4.1.1 U.S.
3.2 Europe
- 3.2.1 Key Market Participants in Europe
- 3.2.2 Business Drivers
- 3.2.3 Business Challenges
  - 3.2.3.1 Europe Metastatic Colorectal Cancer Market, by Country
    - 3.2.3.1.1 Germany
    - 3.2.3.1.2 U.K.
    - 3.2.3.1.3 France
    - 3.2.3.1.4 Italy
    - 3.2.3.1.5 Spain
3.3 Asia-Pacific
- 3.3.1 Key Market Participants in Asia-Pacific
- 3.3.2 Business Drivers
- 3.3.3 Business Challenges
  - 3.3.3.1 Asia-Pacific Metastatic Colorectal Cancer Market, by Country
    - 3.3.3.1.1 Japan

4. Global Metastatic Colorectal Cancer Market: Competitive Landscape and Company Profiles

4.1 Competitive Landscape
- 4.1.1 Key Developments and Strategies
  - 4.1.1.1 Funding Activities
  - 4.1.1.2 Mergers and Acquisitions
  - 4.1.1.3 Regulatory Approvals
  - 4.1.1.4 Partnerships, Collaborations and Business Expansions
4.2 Company Profiles
- 4.2.1 Amgen Inc.
  - 4.2.1.1 Overview
  - 4.2.1.2 Product Portfolio
  - 4.2.1.3 Target Customers
  - 4.2.1.4 Key Professionals
  - 4.2.1.5 Analyst View
- 4.2.2 Pfizer Inc.
  - 4.2.2.1 Overview
  - 4.2.2.2 Product Portfolio
  - 4.2.2.3 Target Customers
  - 4.2.2.4 Key Professionals
  - 4.2.2.5 Analyst View
- 4.2.3 Eli Lilly and Company
  - 4.2.3.1 Overview
  - 4.2.3.2 Product Portfolio
  - 4.2.3.3 Target Customers
  - 4.2.3.4 Key Professionals
  - 4.2.3.5 Analyst View
- 4.2.4 Sanofi
  - 4.2.4.1 Overview
  - 4.2.4.2 Product Portfolio
  - 4.2.4.3 Target Customers
  - 4.2.4.4 Key Professionals
  - 4.2.4.5 Analyst View
- 4.2.5 Merck KGaA
  - 4.2.5.1 Overview
  - 4.2.5.2 Product Portfolio
  - 4.2.5.3 Target Customers
  - 4.2.5.4 Key Professionals
  - 4.2.5.5 Analyst View
- 4.2.6 Novartis AG
  - 4.2.6.1 Overview
  - 4.2.6.2 Product Portfolio
  - 4.2.6.3 Target Customers
  - 4.2.6.4 Key Professionals
  - 4.2.6.5 Analyst View
- 4.2.7 Takeda Pharmaceutical Company Limited
  - 4.2.7.1 Overview
  - 4.2.7.2 Product Portfolio
  - 4.2.7.3 Target Customers
  - 4.2.7.4 Key Professionals
  - 4.2.7.5 Analyst View
- 4.2.8 Taiho Oncology
  - 4.2.8.1 Overview
  - 4.2.8.2 Product Portfolio
  - 4.2.8.3 Target Customers
  - 4.2.8.4 Key Professionals
  - 4.2.8.5 Analyst View
- 4.2.9 Bristol-Myers Squibb Company
  - 4.2.9.1 Overview
  - 4.2.9.2 Product Portfolio
  - 4.2.9.3 Target Customers
  - 4.2.9.4 Key Professionals
  - 4.2.9.5 Analyst View
- 4.2.10 Johnson & Johnson Services, Inc.
  - 4.2.10.1 Overview
  - 4.2.10.2 Product Portfolio
  - 4.2.10.3 Target Customers
  - 4.2.10.4 Key Professionals
  - 4.2.10.5 Analyst View
- 4.2.11 Shanghai Henlius Biotech
  - 4.2.11.1 Overview
  - 4.2.11.2 Product Portfolio
  - 4.2.11.3 Target Customers
  - 4.2.11.4 Key Professionals
  - 4.2.11.5 Analyst View
- 4.2.12 Inspirna
  - 4.2.12.1 Overview
  - 4.2.12.2 Product Portfolio
  - 4.2.12.3 Target Customers
  - 4.2.12.4 Key Professionals
  - 4.2.12.5 Analyst View
- 4.2.13 Treos Bio
  - 4.2.13.1 Overview
  - 4.2.13.2 Product Portfolio
  - 4.2.13.3 Target Customers
  - 4.2.13.4 Key Professionals
  - 4.2.13.5 Analyst View

5. Research Methodology

簡介目錄圖表

List of Figures

Figure: Global Metastatic Colorectal Cancer Market, Market Overview
Figure: Global Metastatic Colorectal Cancer Market, Epidemiological Analysis
Figure: Global Metastatic Colorectal Cancer Market Coverage
Figure: Global Metastatic Colorectal Cancer Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Metastatic Colorectal Cancer Market, Competitive Landscape, January 2022-April 2025